Pancreatology最新文献

英文中文

Nutritional evolution after pancreatoduodenectomy. Is there differences depending on the pancreatic anastomosis (Pancreatogastrostomy vs Pancreatoyeyunostomy)? 胰十二指肠切除术后的营养演变。胰胃吻合术（胰胃吻合术）与胰肺吻合术（胰胃吻合术）是否有差异？

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1016/j.pan.2026.01.035

S. Mansilla Díaz, L.C. Hinojosa Arco, R. Gómez Pérez, A. de Laguno de Luna, J. Roldán de la Rua, J.M. García Almeida, R. de Luna Díaz, M.A. Suárez Muñoz

引用次数: 0

EUS-guided gastroenterostomy with lumen-apposing metal stents: comparison between fluoroscopic and non-fluoroscopic techniques in malignant duodenal obstruction eus引导下置管金属支架胃造口术：恶性十二指肠梗阻的透视与非透视技术比较

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1016/j.pan.2026.01.047

A.M. Hernández Pérez, A. Sánchez Yagüe, R. Rivera Irigoin, J.K. Bisso Zein, C. Verdejo Gil, A. Pérez Aisa

引用次数: 0

In memoriam: Eugene P. DiMagno, MD 1937-2025 纪念：Eugene P. DiMagno, 1937-2025

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1016/j.pan.2026.02.009

Peter Layer , Gerald Holtmann , Peter Malfertheiner , Alberto Maringhini , Massimo Raimondo , Suresh T. Chari

引用次数: 0

Clinical manifestations and response to treatment in patients with autoinmune pancreatitis type 1 related to IgG4: Experience in a tertiary care hospital 与IgG4相关的1型自身免疫性胰腺炎的临床表现和治疗反应：三级医院的经验

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1016/j.pan.2026.01.020

R.M. Vallejo Vigo, L. Álvarez Ortiz, E. Rubio Romero, G. Ontanilla Clavijo

引用次数: 0

Analysis of the effectiveness of therapeutic plasma exchange in the resolution of organ failure in hypertriglyceridemia-induced acute pancreatitis 血浆置换治疗高甘油三酯血症致急性胰腺炎脏器功能衰竭的疗效分析

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1016/j.pan.2026.01.022

S. Homdedeu, S. Salord, L. Secanella, N. Peláez, M. Sorribas, D. Ortiz, E. Santafosta, K. Auquilla, N. García, J. Busquets

引用次数: 0

Objective measurement of plasma fluid deficit, sequestration and redistribution of fluid in body compartments in patients with predicted severe acute pancreatitis 目的测定预测的重症急性胰腺炎患者血浆亏缺、体液在体室的隔离和再分配。

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-01-12 DOI: 10.1016/j.pan.2025.12.027

Rahul Sethia , Soumya Jagannath Mahapatra , Saransh Jain , Swatantra Gupta , Varun Teja , Tanmay Bajpai , Anshuman Elhence , Deepak Gunjan , Sandeep Mahajan , Chandrashekhar Bal , Praveen Aggarwal , Pramod Kumar Garg

Background

Fluid resuscitation is critical in patients with acute pancreatitis (AP) but there is no consensus regarding the amount of fluid to be infused. This is primarily due to difficulty in assessing the fluid deficit accurately. Our objective was to measure the amount of fluid sequestration and intravascular plasma volume deficit by measuring fluid in various body compartments in patients with AP.

Methods

Patients with predicted severe AP presenting within 72 h of onset of pain were included prospectively. These patients underwent analysis of the body fluid composition (distribution of fluid in different compartments) by the Body Composition Monitor, a whole-body multifrequency bioimpedance analysis device. Total body water (TBW), intracellular fluid (ICF), and extracellular fluid (ECF) were measured. Intravascular plasma volume was measured objectively by ⁵¹Chromium radio-isotope labelled RBCs dilution method. Fluid sequestration in the interstitial compartment was calculated based on the fluid distribution.

Results

Twenty patients with predicted severe AP were included in the study [median age 37 years, 75 % male]. The median measured ECF was 13.8 (9.9–18.8) L [58.6 % increase], ICF was 16.3 (10.4–23.3) L [20.1 % decrease], and interstitial fluid volume was 12.7 (8.9–16.3) L [101 % increase] at 48 h after hospitalization. The median plasma volume was 1.4 (0.5–2.3) L at 48 h as compared to 2.4 (1.6–3.1) L at baseline i.e. 48.6 % decrease with a plasma volume deficit of 1.1 (0.4–2.0) L. Fluid sequestration was 2.5 (1.2–3.7) L as per bioimpedance method.

Conclusion

The objective measurement of fluid distribution in body compartments revealed a modest plasma volume deficit in AP, supporting the rationale behind moderate fluid therapy to replenish the plasma volume deficit, rather than the total fluid sequestered in the interstitium.

背景：液体复苏对急性胰腺炎（AP）患者至关重要，但对于输注液体的量尚无共识。这主要是由于难以准确评估体液不足。我们的目的是通过测量AP患者各体室的液体来测量液体潴留量和血管内血浆容量赤字。方法：前瞻性纳入了在疼痛发作72小时内出现预测严重AP的患者。这些患者通过全身多频生物阻抗分析装置——身体成分监测仪（body composition Monitor）分析体液成分（液体在不同隔室的分布）。测定全身水分（TBW）、细胞内液（ICF）和细胞外液（ECF）。采用51Chromium放射性同位素标记红细胞稀释法客观测定血管内血浆体积。根据流体分布计算了间质室的固液量。结果：20例预测为严重AP的患者纳入研究[中位年龄37岁，75%为男性]。住院后48 h中位ECF为13.8 (9.9-18.8)L，升高58.6%，ICF为16.3 (10.4-23.3)L，降低20.1%，间质液容积为12.7 (8.9-16.3)L，升高101%。48小时的中位血浆容量为1.4 (0.5-2.3)L，而基线时为2.4 (1.6-3.1)L，即减少48.6%，血浆容量赤字为1.1 (0.4-2.0)L，根据生物阻抗法，液体隔离为2.5 (1.2-3.7)L。结论：体腔内液体分布的客观测量显示，AP存在适度的血浆容量不足，这支持了适度的液体治疗来补充血浆容量不足的理论基础，而不是在间质中隔离的总液体。

{"title":"Objective measurement of plasma fluid deficit, sequestration and redistribution of fluid in body compartments in patients with predicted severe acute pancreatitis","authors":"Rahul Sethia , Soumya Jagannath Mahapatra , Saransh Jain , Swatantra Gupta , Varun Teja , Tanmay Bajpai , Anshuman Elhence , Deepak Gunjan , Sandeep Mahajan , Chandrashekhar Bal , Praveen Aggarwal , Pramod Kumar Garg","doi":"10.1016/j.pan.2025.12.027","DOIUrl":"10.1016/j.pan.2025.12.027","url":null,"abstract":"<div><h3>Background</h3><div>Fluid resuscitation is critical in patients with acute pancreatitis (AP) but there is no consensus regarding the amount of fluid to be infused. This is primarily due to difficulty in assessing the fluid deficit accurately. Our objective was to measure the amount of fluid sequestration and intravascular plasma volume deficit by measuring fluid in various body compartments in patients with AP.</div></div><div><h3>Methods</h3><div>Patients with predicted severe AP presenting within 72 h of onset of pain were included prospectively. These patients underwent analysis of the body fluid composition (distribution of fluid in different compartments) by the Body Composition Monitor, a whole-body multifrequency bioimpedance analysis device. Total body water (TBW), intracellular fluid (ICF), and extracellular fluid (ECF) were measured. Intravascular plasma volume was measured objectively by <sup>51</sup>Chromium radio-isotope labelled RBCs dilution method. Fluid sequestration in the interstitial compartment was calculated based on the fluid distribution.</div></div><div><h3>Results</h3><div>Twenty patients with predicted severe AP were included in the study [median age 37 years, 75 % male]. The median measured ECF was 13.8 (9.9–18.8) L [58.6 % increase], ICF was 16.3 (10.4–23.3) L [20.1 % decrease], and interstitial fluid volume was 12.7 (8.9–16.3) L [101 % increase] at 48 h after hospitalization. The median plasma volume was 1.4 (0.5–2.3) L at 48 h as compared to 2.4 (1.6–3.1) L at baseline i.e. 48.6 % decrease with a plasma volume deficit of 1.1 (0.4–2.0) L. Fluid sequestration was 2.5 (1.2–3.7) L as per bioimpedance method.</div></div><div><h3>Conclusion</h3><div>The objective measurement of fluid distribution in body compartments revealed a modest plasma volume deficit in AP, supporting the rationale behind moderate fluid therapy to replenish the plasma volume deficit, rather than the total fluid sequestered in the interstitium.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"26 2","pages":"Pages 215-220"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146011639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From static snapshots to spatial evolution: reconstructing the malignant progression from IPMN to invasive PDAC 从静态快照到空间演化：重建从IPMN到侵袭性PDAC的恶性进展。

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-01-19 DOI: 10.1016/j.pan.2026.01.004

Haoran Qi , He Jiang , Mingyang Liu

引用次数: 0

Patient experience with endoscopic ultrasound and magnetic resonance cholangiopancreatography for pancreatic cancer screening (The PATRIOT study) 内镜超声和磁共振胰胆管造影用于胰腺癌筛查的患者经验（爱国者研究）。

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2025-12-29 DOI: 10.1016/j.pan.2025.12.024

Andy Silva-Santisteban Merino , Kevin Enrique Ariza Manzano , Sarah Ballou, Abraham Fourie Bezuidenhout, Katharine A. Germansky, Mandeep S. Sawhney

Background

EUS and MRCP are considered equivalent for pancreatic cancer screening. ASGE guidelines suggest that the choice between these modalities should be based upon patient preferences, however, there is limited data to help guide clinicians.

Methods

All consecutive patients undergoing pancreatic cancer screening who had undergone both EUS and MRCP between 2021 and 2024 were identified. We also selected a comparison cohort of patients undergoing pancreatic cyst surveillance. A survey to elicit patient preferences and experience regarding physical discomfort, anxiety, dread, convenience, reassurance and cancer worry was administered to both groups.

Results

Of 150 pancreatic cancer screening patients approached, 74 % agreed to participate. We compared mean response scores between EUS and MRCP and found patients favored EUS: less claustrophobia(p = 0.001), less dread(p = 0.02), more reassurance(p = 0.01), and more likely to recommend to family(p = 0.059). While 41.4 % reported no overall preference, 33.3 % preferred EUS and 25.2 % MRCP. Of 70/150(47 %) pancreatic cyst surveillance patients who responded, no difference in anxiety, dread or reassurance was noted between EUS and MRCP, but patients reported more claustrophobia with MRCP(p = 0.001). However, patients were more likely to recommend MRCP to family(p = 0.055). While 36.8 % reported no overall preference, 44.1 % preferred MRCP and 19.1 % EUS. Higher levels of cancer worry were reported by screening than cyst surveillance patients, but both groups reported that this rarely interfered with daily activities.

Conclusions

Almost 60 % of patients prefer one screening modality over the other, with a trend towards screening patients favoring EUS and cyst surveillance patients MRCP. These findings support a patient-centered individualized approach to pancreatic cancer screening.

背景：EUS和MRCP在胰腺癌筛查中被认为是等效的。ASGE指南建议，在这些模式之间的选择应基于患者的偏好，然而，有有限的数据来帮助指导临床医生。方法：所有在2021年至2024年间连续接受EUS和MRCP筛查的胰腺癌患者均被确定。我们还选择了一组接受胰腺囊肿监测的患者作为对照。研究人员对两组患者进行了一项调查，以了解患者对身体不适、焦虑、恐惧、便利、安慰和癌症担忧的偏好和体验。结果：在150名胰腺癌筛查患者中，74%的人同意参加。我们比较了EUS和MRCP的平均反应评分，发现患者更喜欢EUS：幽闭恐惧症更少（p = 0.001），恐惧更少（p = 0.02），更放心（p = 0.01），更可能向家人推荐（p = 0.059）。41.4%的人没有总体偏好，33.3%的人选择EUS， 25.2%的人选择MRCP。在70/150（47%）应答的胰腺囊肿监测患者中，EUS和MRCP在焦虑、恐惧或安心方面没有差异，但MRCP患者报告的幽闭恐惧症更多（p = 0.001）。然而，患者更倾向于向家人推荐MRCP （p = 0.055）。36.8%的人没有总体偏好，44.1%的人选择MRCP， 19.1%的人选择EUS。与囊肿监测患者相比，接受筛查的患者对癌症的担忧程度更高，但两组患者都报告说，这很少影响日常活动。结论：近60%的患者更喜欢其中一种筛查方式，倾向于EUS筛查患者和MRCP囊肿监测患者。这些发现支持以患者为中心的个体化胰腺癌筛查方法。

{"title":"Patient experience with endoscopic ultrasound and magnetic resonance cholangiopancreatography for pancreatic cancer screening (The PATRIOT study)","authors":"Andy Silva-Santisteban Merino , Kevin Enrique Ariza Manzano , Sarah Ballou, Abraham Fourie Bezuidenhout, Katharine A. Germansky, Mandeep S. Sawhney","doi":"10.1016/j.pan.2025.12.024","DOIUrl":"10.1016/j.pan.2025.12.024","url":null,"abstract":"<div><h3>Background</h3><div>EUS and MRCP are considered equivalent for pancreatic cancer screening. ASGE guidelines suggest that the choice between these modalities should be based upon patient preferences, however, there is limited data to help guide clinicians.</div></div><div><h3>Methods</h3><div>All consecutive patients undergoing pancreatic cancer screening who had undergone both EUS and MRCP between 2021 and 2024 were identified. We also selected a comparison cohort of patients undergoing pancreatic cyst surveillance. A survey to elicit patient preferences and experience regarding physical discomfort, anxiety, dread, convenience, reassurance and cancer worry was administered to both groups.</div></div><div><h3>Results</h3><div>Of 150 pancreatic cancer screening patients approached, 74 % agreed to participate. We compared mean response scores between EUS and MRCP and found patients favored EUS: less claustrophobia(p = 0.001), less dread(p = 0.02), more reassurance(p = 0.01), and more likely to recommend to family(p = 0.059). While 41.4 % reported no overall preference, 33.3 % preferred EUS and 25.2 % MRCP. Of 70/150(47 %) pancreatic cyst surveillance patients who responded, no difference in anxiety, dread or reassurance was noted between EUS and MRCP, but patients reported more claustrophobia with MRCP(p = 0.001). However, patients were more likely to recommend MRCP to family(p = 0.055). While 36.8 % reported no overall preference, 44.1 % preferred MRCP and 19.1 % EUS. Higher levels of cancer worry were reported by screening than cyst surveillance patients, but both groups reported that this rarely interfered with daily activities.</div></div><div><h3>Conclusions</h3><div>Almost 60 % of patients prefer one screening modality over the other, with a trend towards screening patients favoring EUS and cyst surveillance patients MRCP. These findings support a patient-centered individualized approach to pancreatic cancer screening.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"26 2","pages":"Pages 259-264"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146030355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High prevalence of anxiety and depression among patients with acute and chronic pancreatitis: A systematic review and meta-analysis 急性和慢性胰腺炎患者焦虑和抑郁的高患病率：一项系统回顾和荟萃分析。

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-01-22 DOI: 10.1016/j.pan.2026.01.006

Tibor Dániel Fehér , Mahmoud Obeidat , Boglárka Lilla Szentes , Renáta Papp , Brigitta Teutsch , Marie Anne Engh , Szilárd Váncsa , Réka Csaba , Lilla Réthy , Péter Hegyi , Rita Nagy

Background

Depression and anxiety are increasingly recognized as important comorbidities in gastrointestinal (GI) disorders, influencing disease burden and patient outcomes. However, their prevalence in pancreatitis, both in its acute (AP) and chronic (CP) forms, remains underexplored. This systematic review and meta-analysis aimed to quantify the burden of depressive and anxiety symptoms among patients with pancreatitis.

Methods

We conducted a systematic search (PROSPERO: CRD42023481739) across three databases: MEDLINE, Embase, and CENTRAL, to identify studies reporting on the prevalence of depression and anxiety symptoms in patients with AP or CP, as of November 10, 2023. The random-effects model was used to calculate the pooled proportion rate and pooled means of different anxiety/depression scores, along with 95 % confidence intervals (CI).

Results

In total, 44 studies were included. Anxiety was observed in 23 % (CI: 7 %–54 %) of the AP cases, and it was observed in 31 % (CI: 23 %–39 %) of the CP cases. Depressive symptoms were observed in 29 % (CI: 14 %–51 %) of the AP patients, while in CP cases, the prevalence was 39 % (CI: 30 %–48 %). The pooled single-mean analysis of psychological questionnaire data confirms clinically significant levels of both depressive and anxiety symptoms. Mean scores exceeded established cut-off points across all measures: CESD-10 (14.30 [CI: 6.69–21.92]), HADS-depression (8.23 [CI: 4.53–11.94]), SES (49.29 [CI: 44.01–54.57]), HADS-anxiety (8.67 [CI: 6.89–10.46]), and SAS (47.75 [CI: 35.05–60.45]). These findings indicate that many participants experienced symptom levels beyond the normative range. Overall, a low risk of bias was observed; however, several studies were identified as high risk due to reporting limitations.

Conclusions

Our findings reveal a notably high prevalence of depression and anxiety in pancreatitis, exceeding global averages and rates seen in other GI disorders. These findings warrant routine psychological screening, ongoing follow-up, and the integration of mental health professionals into multidisciplinary care teams are therefore warranted.

背景：抑郁和焦虑越来越被认为是胃肠道（GI）疾病的重要合并症，影响疾病负担和患者预后。然而，它们在急性（AP）和慢性（CP）形式的胰腺炎中的患病率仍未得到充分探讨。本系统综述和荟萃分析旨在量化胰腺炎患者抑郁和焦虑症状的负担。方法：我们对MEDLINE、Embase和CENTRAL三个数据库进行了系统检索（PROSPERO: CRD42023481739），以确定截至2023年11月10日有关AP或CP患者抑郁和焦虑症状患病率的研究报告。采用随机效应模型计算不同焦虑/抑郁评分的合并比例率和合并均值，并计算95%置信区间（CI）。结果：共纳入44项研究。23%的AP病例（CI: 7% - 54%）出现焦虑，31%的CP病例（CI: 23% - 39%）出现焦虑。在29%的AP患者（CI: 14% - 51%）中观察到抑郁症状，而在CP病例中，患病率为39% （CI: 30% - 48%）。对心理问卷数据的汇总单均值分析证实了抑郁和焦虑症状的临床显著水平。所有测量的平均得分都超过了既定的截止点：csd -10 （14.30 [CI: 6.69-21.92]）、hads -抑郁（8.23 [CI: 4.53-11.94]）、SES （49.29 [CI: 44.01-54.57]）、hads -焦虑（8.67 [CI: 6.89-10.46]）和SAS （47.75 [CI: 35.05-60.45]）。这些发现表明，许多参与者经历的症状水平超出了标准范围。总体而言，观察到低偏倚风险；然而，由于报告的局限性，一些研究被确定为高风险。结论：我们的研究结果显示，胰腺炎患者中抑郁和焦虑的患病率明显较高，超过了全球平均水平和其他胃肠道疾病的发生率。这些发现证明有必要进行常规的心理筛查，持续的随访，并将精神卫生专业人员纳入多学科护理团队。

{"title":"High prevalence of anxiety and depression among patients with acute and chronic pancreatitis: A systematic review and meta-analysis","authors":"Tibor Dániel Fehér , Mahmoud Obeidat , Boglárka Lilla Szentes , Renáta Papp , Brigitta Teutsch , Marie Anne Engh , Szilárd Váncsa , Réka Csaba , Lilla Réthy , Péter Hegyi , Rita Nagy","doi":"10.1016/j.pan.2026.01.006","DOIUrl":"10.1016/j.pan.2026.01.006","url":null,"abstract":"<div><h3>Background</h3><div>Depression and anxiety are increasingly recognized as important comorbidities in gastrointestinal (GI) disorders, influencing disease burden and patient outcomes. However, their prevalence in pancreatitis, both in its acute (AP) and chronic (CP) forms, remains underexplored. This systematic review and meta-analysis aimed to quantify the burden of depressive and anxiety symptoms among patients with pancreatitis.</div></div><div><h3>Methods</h3><div>We conducted a systematic search (PROSPERO: CRD42023481739) across three databases: MEDLINE, Embase, and CENTRAL, to identify studies reporting on the prevalence of depression and anxiety symptoms in patients with AP or CP, as of November 10, 2023. The random-effects model was used to calculate the pooled proportion rate and pooled means of different anxiety/depression scores, along with 95 % confidence intervals (CI).</div></div><div><h3>Results</h3><div>In total, 44 studies were included. Anxiety was observed in 23 % (CI: 7 %–54 %) of the AP cases, and it was observed in 31 % (CI: 23 %–39 %) of the <u>CP</u> cases. Depressive symptoms were observed in 29 % (CI: 14 %–51 %) of the AP patients, while in CP cases, the prevalence was 39 % (CI: 30 %–48 %). The pooled single-mean analysis of psychological questionnaire data confirms clinically significant levels of both depressive and anxiety symptoms. Mean scores exceeded established cut-off points across all measures: CESD-10 (14.30 [CI: 6.69–21.92]), HADS-depression (8.23 [CI: 4.53–11.94]), SES (49.29 [CI: 44.01–54.57]), HADS-anxiety (8.67 [CI: 6.89–10.46]), and SAS (47.75 [CI: 35.05–60.45]). These findings indicate that many participants experienced symptom levels beyond the normative range. Overall, a low risk of bias was observed; however, several studies were identified as high risk due to reporting limitations.</div></div><div><h3>Conclusions</h3><div>Our findings reveal a notably high prevalence of depression and anxiety in pancreatitis, exceeding global averages and rates seen in other GI disorders. These findings warrant routine psychological screening, ongoing follow-up, and the integration of mental health professionals into multidisciplinary care teams are therefore warranted.</div></div>","PeriodicalId":19976,"journal":{"name":"Pancreatology","volume":"26 2","pages":"Pages 221-230"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bile liquid biopsy improves detection of actionable mutations in early pancreatic ductal adenocarcinoma 胆汁液活检提高了早期胰腺导管腺癌可操作突变的检测

IF 2.7 2区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Pancreatology

Pub Date : 2026-03-01 Epub Date: 2026-03-02 DOI: 10.1016/j.pan.2026.01.065

D. Oyón , M. Rullán , J. Rández-Garbayo , A. Fernández-Atutxa , D. Ruiz-Clavijo , B. González de la Higuera , F. Bolado , I. Amat , D. Guerrero , J. Carrascosa , V. Jusué , I. Fernández-Urién , M. Arechederra , C. Berasain , J.J. Vila , M. Ávila , J.M. Urman

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Pancreatology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀